MIF and COVID-19: It is of interest in this context and as regards the translatability of the emerging finding of MIF and D-DT in COVID-19 that there are two clinical studies that aim at evaluating the effects of the semi-specific inhibitor of MIF, Ibudilast, on the course of the disease (NCT04429555; NCT05513560) and one specifically designed to treat patients with lingering symptoms of COVID-19 (Long COVID).